Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC—ECSG phase II clinical study

Teresa Gamucci, A.-R. Hanauske(KU Leuven), Nikolaos Pavlidis(University Hospital of Ioannina), R Paridaens(KU Leuven), Jan H.M. Schellens(Utrecht University), S.B. Kaye(Western Infirmary), Jaap Verweij(Deutz (Germany)), Bernhard Heinrich(TUM Klinikum), J. Wanders(Eisai (United Kingdom)), Cristiana Sessa(Institute of Oncology Research), M. Roelvink
Annals of Oncology
July 1, 2000
10.1023/a:1008373031714
Cited by 26

Related Papers

Cremophor EL
|European Journal of Cancer|2001|1.6k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k